**Highlights of This Issue 2251**

### SMALL MOLECULE THERAPEUTICS

2253  | The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation  

2264  | Inhibition of Endoglin–GIPC Interaction Inhibits Pancreatic Cancer Cell Growth  

2276  | Drug Repurposing Identifies a Synergistic Combination Therapy with Imatinib Mesylate for Gastrointestinal Stromal Tumor  
Ziyan Y. Pessetto, Yan Ma, Jeff J. Hirst, Margaret von Mehren, Scott J. Weir, and Andrew K. Godwin

2288  | Synergistic Simvastatin and Metformin Combination Chemotherapy for Osseous Metastatic Castration-Resistant Prostate Cancer  
Melissa A. Babcook, Sanjeev Shukla, Pingfu Fu, Edwin J. Vazquez, Michelle A. Puchowicz, Joseph P. Molter, Christine Z. Oak, Gregory T. MacLennan, Chris A. Flask, Daniel J. Lindner, Yvonne Parker, Firouz Baneshgari, and Sanjay Gupta

### LARGE MOLECULE THERAPEUTICS

2341  | Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α  
Edmund A. Rossi, Diane L. Rossi, Thomas M. Cardillo, Chien-Hsing Chang, and David M. Goldenberg

### CANCER BIOLOGY AND SIGNAL TRANSDUCTION

2361  | Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer  

2372  | Prostate Cancer Cell Response to Paclitaxel Is Affected by Abnormally Expressed Securin PTTG1  
Carolina Castillo, M. Luz Flores, Rafael Medina, Begona Pérez-Valderrama, Francisco Romero, María Tortolero, Miguel A. Japón, and Carmen Sáez

2384  | Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress–Inducing Drugs  
Laurence Booth, Jane L. Roberts, Nichola Cruickshanks, Steven Grant, Andrew Poklepovic, and Paul Dent

2399  | Temozolomide Induces the Production of Epidermal Growth Factor to Regulate MDR1 Expression in Glioblastoma Cells  
Jessian L. Munoz, Vivian Rodriguez-Cruz, Steven J. Greco, Vipul Nagula, Kathleen W. Scotto, and Pranela Rameshwar
Table of Contents

2412  **BRCA2 and RAD51 Promote Double-Strand Break Formation and Cell Death in Response to Gemcitabine**  
Rebecca M. Jones, Panagiotis Kotsantis, Grant S. Stewart, Petra Groth, and Eva Petermann

2422  **Piperlongumine Chemosensitizes Tumor Cells through Interaction with Cysteine 179 of IκBα Kinase, Leading to Suppression of NF-κB–Regulated Gene Products**  
Jia Gang Han, Subash C. Gupta, Sahdeo Prasad, and Bharat B. Aggarwal

2436  **Calpain-Mediated Integrin Deregulation as a Novel Mode of Action for the Anticancer Gallium Compound KP46**  

MODELS AND TECHNOLOGIES

2450  **An In Vivo Antilymphatic Screen in Zebrafish Identifies Novel Inhibitors of Mammalian Lymphangiogenesis and Lymphatic-Mediated Metastasis**  
Jonathan W. Astin, Stephen M.P. Jamieson, Tiffany C.Y. Eng, Maria V. Flores, June P. Misa, Annie Chien, Kathryn E. Crosier, and Philip S. Crosier

2463  **Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4D**  
Ningning He, Nayoung Kim, Mee Song, Cha Park, Somin Kim, Eun Young Park, Hwa Young Yim, Kyunga Kim, Jong Hoon Park, Keun Il Kim, Fan Zhang, Gordon B. Mills, and Sukjoon Yoon

ABOUT THE COVER

Zebrafish embryos can be used to examine mechanisms of vascular development and as a platform with which to identify novel antivascular agents; this is an image of a 2-day-old zebrafish embryo showing developing lymphatic vessels in green (lyve1:egfp) and endothelial cell nuclei in red (kdrl:nls:mcherry). This embryo was live imaged for a further 20 hours to identify novel inhibitors of lymphatic vessel growth and revealed that flunarizine, a calcium channel antagonist, was able specifically induce lymphatic endothelial cell death. For details, see the article by Astin and colleagues on page 2450.